Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.

This study was sponsored by Pfizer Inc. L. Bessette, MD, MSc, Department of Medicine, Laval University, Quebec, Quebec, Canada; E. Mysler, MD, Organización Médica de Investigación, Buenos Aires, Argentina; C.D. Kinch, PhD, P.V. On, MSc, Pfizer Canada ULC, Kirkland, Quebec, Canada; K. Kwok, MS, T. Lukic, MD, MSc, Pfizer Inc, New York, New York, USA; R.F. van Vollenhoven, MD, PhD, Amsterdam Rheumatology and Immunology Center, and Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, The Netherlands. LB has received grants and/or research support from AbbVie, Amgen, BMS, Celgene, Janssen, Eli Lilly, Gilead Sciences, Novartis, Pfizer Inc, Roche, Sanofi, and UCB; and has acted as a consultant or speaker for AbbVie, Celgene, Eli Lilly, Fresenius Kabi, Gilead Sciences, Novartis, Pfizer Inc, and Sandoz. EM has received research grants from Eli Lilly, Pfizer Inc, and Roche; and serves on speakers' bureaus for AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. CDK, KK, TL, and PVO are employees and stockholders of Pfizer Inc. RFvV has received grants and/or research support from AbbVie, Amgen, BMS, GSK, Pfizer Inc, Roche, and UCB; and has acted as a consultant for AbbVie, AstraZeneca, Biotest, BMS, Celgene, Crescendo, Eli Lilly, GSK, Janssen, Merck, Novartis, Pfizer Inc, Roche, UCB, and Vertex. Address correspondence to Dr. C.D. Kinch, Pfizer Canada ULC, 17300 Trans-Canada Hwy, Kirkland, QC, Canada H9J 2M5. Email: Cassandra.Kinch@pfizer.com. Accepted for publication February 9, 2022.